With the FDA approval of ORZEYFUL (obeporepton), it is approved as the first orexin receptor agonist for NT1 treatment. After DEA classification review is completed, it will be launched in the U.S. market via specialty pharmacies. Impact on full-year consolidated results for FY2027 is not currently expected to be significant.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4502","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4502-20260806-01.pdf","jir_short_summary":"With the FDA approval of ORZEYFUL (obeporepton), it is approved as the first orexin receptor agonist for NT1 treatment. After DEA classification review is completed, it will be launched in the U.S. market via specialty pharmacies. Impact on full-year consolidated results for FY2027 is not currently expected to be significant.","jir_summary":"### Overview of the News\nTakeda Pharmaceutical announced that it has obtained FDA approval for ORZEYFUL (obeporepton). For NT1, this drug demonstrates multiple symptom improvements during daytime and nighttime and is approved as the first orexin receptor agonist. Once the DEA classification review is completed, it will be available in the U.S. market via specialty pharmacies.\n\n### Outlook and Impact\nDEA classification decision is expected within 90 days after FDA approval, and after approval, treatment options for NT1 patients will expand. This approval is not expected to have a material impact on the full-year consolidated earnings forecast for FY2027. Obeporepton provides a new mechanism of action as an orexin receptor agonist for NT1 treatment.","jir_financial_highlights":"Unclear: Unclear (Unclear)\nUnclear: Unclear (Unclear)\nUnclear: Unclear (Unclear)","jir_category":"","jir_hashtags":"#TakedaPharmaceutical, #ORZEYFUL, #NT1, #Orexin, #FDAApproval","jir_key_figures":"Approval date: 2026-08-05 (FDA approval mentioned)\nDEA classification decision: expected within 90 days\nFuture launch: planned via specialty pharmacies","jir_meta_title":"Takeda Pharmaceutical: NT1 Treatment ORZEYFUL to Receive FDA Approval | August 2026","jir_meta_description":"Takeda's new drug ORZEYFUL (obeporepton) obtains FDA approval. Provides a new option for NT1 treatment. After DEA classification, U.S. market launch planned. FY2027 earnings impact undecided.","jir_og_title":"Takeda Pharmaceutical | ORZEYFUL FDA Approval for NT1 Treatment","jir_og_description":"ORZEYFUL approved by FDA, expanding treatment options for NT1. DEA classification will follow, with U.S. market launch planned.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6852,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-95963","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n